{
    "root": "25316ee2-99e4-44f0-bb74-de56961ecfda",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "JYLAMVO",
    "value": "20250428",
    "ingredients": [
        {
            "name": "METHOTREXATE",
            "code": "YL5FZ2Y5U1"
        },
        {
            "name": "POLYETHYLENE GLYCOL",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX"
        },
        {
            "name": "SUCRALOSE",
            "code": "96K6UQ3ZD4"
        },
        {
            "name": "ETHYLPARABEN",
            "code": "14255EXE39"
        },
        {
            "name": "METHYLPARABEN SODIUM",
            "code": "CR6K9C2NHK"
        },
        {
            "name": "CITRIC ACID MONOHYDRATE",
            "code": "2968PHW8QP"
        },
        {
            "name": "SODIUM CITRATE",
            "code": "1Q73Q2JULR"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        }
    ],
    "indications": "JYLAMVO is a folate analog metabolic inhibitor indicated for the: Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen ( 1.1 ) Treatment of adults with mycosis fungoides ( 1.1 ) Treatment of adults with relapsed or refractory non-Hodgkin lymphoma as part of a metronomic combination regimen ( 1.1 ) Treatment of adults with rheumatoid arthritis ( 1.2 ) Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA) ( 1.3 ) Treatment of adults with severe psoriasis (1.4 )",
    "contraindications": "Verify pregnancy status in females of reproductive potential before starting JYLAMVO. ( 2.1, 4, 5.1 ) Instruct patients and caregivers to take the recommended dosage as directed, because medication errors have led to deaths. ( 2.1, 5.9 ) ALL : The recommended dosage is 20 mg/m 2 orally once weekly as a part of a combination chemotherapy maintenance regimen. ( 2.2 ) Mycosis fungoides : The recommended dosage is 25 mg to 75 mg orally once weekly as monotherapy; 10 mg/m 2 orally twice weekly as part of combination chemotherapy. ( 2.2 ) Relapsed or refractory non-Hodgkin lymphoma : The recommended dosage is 2.5 mg orally two to four times per week as part of metronomic combination chemotherapy. ( 2.2 ) Rheumatoid Arthritis : The recommended starting dosage is 7.5 mg orally once weekly; adjust dose to achieve an optimal response. ( 2.3 ) pJIA: The recommended starting dosage is 10 mg/m 2 orally once weekly; adjust dose to achieve an optimal response. ( 2.4 ) Psoriasis : The recommended dosage is 10 mg to 25 mg orally once weekly until adequate response is achieved. ( 2.5 )",
    "warningsAndPrecautions": "JYLAMVO is supplied as a clear yellow oral solution that contains 2 mg of methotrexate per mL. It is packaged in an amber type III glass bottle with tamper evident child-resistant closure (polypropylene with expanded polyethylene liner) containing 60 mL of oral solution.\n                  Each pack contains one bottle, a low-density polyethylene (LDPE) bottle adaptor and a 10 mL white polypropylene dosing syringe (with major graduations at every 1 mL and minor graduations at every 0.25 mL) (NDC 81927-204-01).\n                  Store JYLAMVO at 20°C to 25°C (68°F to 77°F) excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].\n                  In Use storage conditions: Store JYLAMVO at room temperature 20°C to 25°C (68°F to 77°F). Keep the bottle tightly closed. After first opening, discard any unused medicine after 3 months.\n                  JYLAMVO is a hazardous drug. Follow applicable special handling and disposal procedures.1",
    "adverseReactions": "JYLAMVO is contraindicated in:\n                  \n                     Pregnant women for treatment of non-neoplastic diseases [see Warnings and Precautions (5.1),  and Use in Specific Populations (8.1, \n                           8.3)].\n                     Patients with a history of a severe hypersensitivity reactions, including anaphylaxis, to methotrexate [see Warnings and Precautions (5.2)]."
}